biotech – media

Why Small Biotech Needs To Plan Ahead For Global Reach

If small biotech does more to plan ahead for ex-US market requirements, companies and their investors – and crucially patients – will benefit.
- Source: https://invivo.pharmaintelligence.informa.com/IV124998/Missed-Opportunities-Why-Small-Biotech-Needs-To-Plan-Ahead-For-Global-Reach
- 1,716
- April 6, 2022
biotech commercializing
Suven Life Sciences Rises 1% on Patent from Mexico and New Zealand

Neurodegenerative diseases are plenty in number, but to find the ultimate research is still ongoing worldwide. One company involved in this process is Suven Life Sciences. They have discovered novel chemical entities responsible for the treatment of neurodegenerative diseases, which were claimed for patenting.
- Source: MoneyControl
- 709
- August 9, 2018
biotech Company Insight neurodegenerative disease
HitGen and Merck Collaborates For DNA Library Screening

HitGen and Merck have updated their licensing agreement to a full-fledged drug discovery collaboration in order to screen DNA-encoded libraries for new small-molecule assets.
- Source: FierceBiotech
- 1,000
- August 8, 2018
biotech China Company Insight Merck
HiFiBiO Receives New Funding, Inks R&D Deal with Takeda

HiFiBiO Therapeutics is aspiring to work on antibody therapies for different gastrointestinal diseases, cancers and other disorders by signing a pact with Japanese Pharma and biotech company Takeda.
- Source: FierceBiotech
- 759
- August 2, 2018
biotech Company Insight Takeda
Electrocore Releases Gammacore Therapy against Migraine and Episodic Cluster Headaches

ElectroCore, famous for bioelectronic medicines, is associating with UpScriptHealth to deliver its gammaCore treatment via direct-to-patient telemedicine program. This non-invasive stimulation therapy of vagus nerve is used to treat migraines and episodic cluster headaches among the adults.
- Source: FierceBiotech
- 770
- July 19, 2018
biotech cluster headache medtech migraine New Approvals
Spero Gets Grant of $54M for Biodefense R&D for SPR994

Spero Therapeutics granted $15.7 million for research on SPR994, its oral carbapenem-class candidate, to study the drug’s efficacy against biological threats like anthrax, plague and melioidosis as a part of an interagency collaboration.
- Source: FierceBiotech
- 804
- July 18, 2018
biotech Company Insight
Biontech and Genevant Sciences Join Hands to Roll Out Rare Disease Drugs

In a joint venture, German biopharmaceutical firm BioNTech and Genevant Sciences, a genetic disorder therapeutics maker plan to develop mRNA therapy programmes targeting rare diseases with severely deficient medical attention.
- Source: Pharmaceutical Technology
- 747
- July 16, 2018
biotech Company Insight rare diseases
NBE Therapeutics Receives $20 million in Series B by Novo Holdings

Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
- Source: FierceBiotech
- 657
- June 29, 2018
biotech cancer Company Insight
Carisma Therapeutics Bags $53 Million in Series A Funding led by AbbVie

Philadelphia-based Carisma Therapeutics bagged $53 million in series A funding, led by AbbVie Ventures Co-led by HealthCap, new backers Wellington Partners, MRL Ventures Fund, TPG Biotech, and Agent Capital.
- Source: FierceBiotech
- 726
- June 28, 2018
biotech CAR-T therapies Company Insights funding
Biotech Crinetics Therapeutics Raises $86 million in IPO

The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.
- Source: FierceBiotech
- 795
- June 26, 2018
biotech Clinical Trials endocrine disorders

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.